H. Lundbeck A/s
Clinical trials sponsored by H. Lundbeck A/s, explained in plain language.
-
New Parkinson's drug tested for motor symptom control
Disease control CompletedThis early-stage study tested the safety and effects of an experimental drug called Lu AF28996 in people with Parkinson's disease. The 57 participants had motor fluctuations and troublesome dyskinesia despite taking their regular Parkinson's medications. Researchers measured how …
Phase: PHASE1 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Year-Long migraine shot safety check completed
Disease control CompletedThis study aimed to check the long-term safety of a migraine prevention medicine called eptinezumab. It involved 160 Japanese patients with migraine who received the medicine for 60 weeks, followed by 8 weeks of safety monitoring. The main goal was to see how well patients tolera…
Phase: PHASE3 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New injection shows promise in cutting migraine days in half
Disease control CompletedThis large, completed study tested whether a medication called eptinezumab could help prevent migraines in adults who get them very frequently. Nearly 1,000 participants with chronic migraine received either the drug at one of two doses or a placebo injection to see which was bet…
Phase: PHASE3 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New treatment tested to break vicious cycle of migraines and painkiller overuse
Disease control CompletedThis study tested if adding a preventive migraine drug called eptinezumab to a brief educational program helps adults who have frequent migraines and also overuse pain medications for headaches. Over 600 participants were randomly assigned to receive either eptinezumab or a place…
Phase: PHASE4 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Mar 04, 2026 15:29 UTC
-
First safety check for new migraine drug combo
Disease control CompletedThis study tested the safety of a new migraine injection (Lu AG09222) when taken with an existing oral migraine medication (ubrogepant). It involved 43 adults with a history of migraine to see if the combination caused any new or worsening side effects. This was an early-stage tr…
Phase: PHASE1 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Mar 02, 2026 15:25 UTC